Broad Effectiveness: Study With Aripiprazole - Full Text View

Broad Effectiveness: Study With Aripiprazole

This study has been completed.

Sponsors and Collaborators:	Bristol-Myers Squibb Otsuka America Pharmaceutical
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00036361

Purpose

The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders

Condition	Intervention	Phase
Schizophrenia Schizoaffective Disorder	Drug: Aripiprazole	Phase III

MedlinePlus related topics:

Schizophrenia

Drug Information available for:

Aripiprazole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety Study

Official Title:	Broad Effectiveness: Study With Aripiprazole

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:

Safety Assessments

Secondary Outcome Measures:

Safety Assessments

Estimated Enrollment:	444
Study Start Date:	July 2002

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Patients with Schizophrenia or Schizoaffective Disorder

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036361

Locations


United States, Connecticut
	Local Institution
	Wallingford, Connecticut, United States

Sponsors and Collaborators

Bristol-Myers Squibb

Otsuka America Pharmaceutical

More Information

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

Study ID Numbers:	CN138-087
First Received:	May 8, 2002
Last Updated:	June 27, 2008
ClinicalTrials.gov Identifier:	NCT00036361
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Schizophrenia

Mental Disorders

Psychotic Disorders

Aripiprazole

Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Tranquilizing Agents

Therapeutic Uses

Physiological Effects of Drugs

Psychotropic Drugs

Central Nervous System Depressants

Antipsychotic Agents

Central Nervous System Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008